Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...
Adopting zanubrutinib for the treatment of chronic lymphocytic leukemia showed improved tolerability and persistence, ...
Partnership to Advance Blood Cancer United’s Mission Through Philanthropy, Volunteerism, and Exclusive Limited-Edition ...
Young Stewart's battle with Acute Lymphocytic Leukemia showcases resilience and hope, as Palmetto Publishing reveals a family ...
Justin C. Frankel, P.C., represented a client with Chronic Lymphocytic Leukemia whose long-term disability benefits ...
Orphan drug designation is granted by the FDA for therapies treating rare disease affecting fewer than 200,000 patients in the U.S., and provides development incentives including extended market ...
The FDA approved a larger nelarabine vial to improve dosing flexibility and simplify treatment for adult and pediatric ...
The FDA has granted approval to a larger vial size of nelarabine injection (SH-111) for use in treatment of adult and ...
After adjustment for other factors, a CFS of 3 or higher and relapsed/refractory disease were the only independent predictors of early zanubrutinib discontinuation.
CTD402, an allogeneic CAR T-cell therapy, is designed for immediate administration and targets relapsed/refractory T-ALL and ...
Indiana Senate passes Bill 85 to ease medical debt burden and protect low-income earners from wage garnishment.
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $19.5, with a high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results